New Delhi: Pharmaceuticals major Dr Reddy’s Laboratories and its UK-based partner Argenta Discovery today said they have selected the first candidate drug, an anti-inflammatory molecule, for treating chronic respiratory disease, to proceed into pre-clinical development.
“Just 18 months after signing the deal with Dr Reddy’s, the team has already selected the first candidate drug to proceed into pre-clinical development. We are very excited by the exceptional progress this programme has made within such a short time frame,” Argenta’s Chief Executive Officer Christopher Ashton said.
He said with GMP material already manufactured, the partners were on target to enter Phase I in mid-2008 and Phase II in 2009.
“We believe we are first-in-class for this inhaled anti-inflammatory approach to treat chronic respiratory disease,” he added.
This is a big milestone in the development programme targeting a novel disease-modifying approach to treat the underlying cause of certain chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and severe asthma, the companies said in a joint statement.
Ashton said the programme was also likely to deliver high quality back-up candidates in the near future, which is testament to the overall strength and depth of the approach.
Under the terms of the licensing agreement announced in February 2006, Argenta and Dr Reddy’s are collaborating to identify clinical candidates against an undisclosed but proven anti-inflammatory drug target and to develop these candidates to Phase II proof-of-concept.